LIVIVO - Search results -

Search results

Result 1 - 10 of total 103

Search options

Article ; Online: Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply.

Fajgenbaum, David C

2022 Volume 387, Issue 8, Page(s) 763

MeSH term(s)	Fever/etiology ; Humans ; Hyperhidrosis ; Male ; Middle Aged ; Sweat ; Sweating
Language	English
Publishing date	2022-07-21
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMc2208384
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: How we manage idiopathic multicentric Castleman disease.

Brandstadter, Joshua D / Fajgenbaum, David C

Clinical advances in hematology & oncology : H&O

2022 Volume 20, Issue 9, Page(s) 564–571

MeSH term(s)	Castleman Disease/diagnosis ; Castleman Disease/drug therapy ; Humans
Language	English
Publishing date	2022-09-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	2271951-9
ISSN	1543-0790
ISSN	1543-0790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6505: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cytokine Storm. Reply.

Fajgenbaum, David C / June, Carl H

The New England journal of medicine

2021 Volume 384, Issue 16, Page(s) e59

MeSH term(s)	COVID-19 ; Cytokine Release Syndrome ; Cytokines ; Humans
Chemical Substances	Cytokines
Language	English
Publishing date	2021-04-07
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMc2036236
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Fajgenbaum, David C

Hematology. American Society of Hematology. Education Program

2018 Volume 2018, Issue 1, Page(s) 318–325

Abstract: Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy ( ... ...

Abstract	Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). The limited understanding of etiology, cell types, and signaling pathways involved in iMCD has slowed development of treatments and contributed to historically poor patient outcomes. Here, recent progress for diagnosing iMCD, characterizing etio-pathogenesis, and advancing treatments are reviewed. Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clinical subtypes: thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS), which are both observed all over the world. In 2014, the anti-IL-6 therapy siltuximab became the first iMCD treatment approved by the US Food and Drug Administration, on the basis of a 34% durable response rate; consensus guidelines recommend it as front-line therapy. Recent cytokine and proteomic profiling has revealed normal IL-6 levels in many patients with iMCD and potential alternative driver cytokines. Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts did not reveal novel viruses, HHV-8, or other viruses pathologically associated with iMCD. Despite progress, iMCD remains poorly understood. Further efforts to elucidate etiology, pathogenesis, and treatment approaches, particularly for siltuximab-refractory patients, are needed.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Castleman Disease/diagnosis ; Castleman Disease/drug therapy ; Castleman Disease/etiology ; Castleman Disease/metabolism ; Herpesviridae Infections/complications ; Herpesviridae Infections/diagnosis ; Herpesviridae Infections/drug therapy ; Herpesviridae Infections/metabolism ; Herpesvirus 8, Human/metabolism ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/metabolism ; Practice Guidelines as Topic ; Signal Transduction/drug effects
Chemical Substances	Antibodies, Monoclonal ; IL6 protein, human ; Interleukin-6 ; siltuximab (T4H8FMA7IM)
Language	English
Publishing date	2018-11-30
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2084287-9
ISSN	1520-4383 ; 1520-4391
ISSN (online)	1520-4383
ISSN	1520-4391
DOI	10.1182/asheducation-2018.1.318
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Fajgenbaum, David C

Blood

2018 Volume 132, Issue 22, Page(s) 2323–2330

Abstract	Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). The limited understanding of etiology, cell types, and signaling pathways involved in iMCD has slowed development of treatments and contributed to historically poor patient outcomes. Here, recent progress for diagnosing iMCD, characterizing etio-pathogenesis, and advancing treatments are reviewed. Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clinical subtypes: thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS), which are both observed all over the world. In 2014, the anti-IL-6 therapy siltuximab became the first iMCD treatment approved by the US Food and Drug Administration, on the basis of a 34% durable response rate; consensus guidelines recommend it as front-line therapy. Recent cytokine and proteomic profiling has revealed normal IL-6 levels in many patients with iMCD and potential alternative driver cytokines. Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts did not reveal novel viruses, HHV-8, or other viruses pathologically associated with iMCD. Despite progress, iMCD remains poorly understood. Further efforts to elucidate etiology, pathogenesis, and treatment approaches, particularly for siltuximab-refractory patients, are needed.
MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Animals ; Antibodies, Monoclonal/therapeutic use ; Castleman Disease/diagnosis ; Castleman Disease/drug therapy ; Castleman Disease/etiology ; Castleman Disease/immunology ; Disease Management ; Herpesviridae Infections/complications ; Herpesvirus 8, Human/isolation & purification ; Humans ; Immunologic Factors/therapeutic use ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Rituximab/therapeutic use
Chemical Substances	Adrenal Cortex Hormones ; Antibodies, Monoclonal ; Immunologic Factors ; Interleukin-6 ; Rituximab (4F4X42SYQ6) ; siltuximab (T4H8FMA7IM)
Language	English
Publishing date	2018-11-28
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2018-05-848671
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases.

Korsunska, Ania / Repasky, Mileva / Zuccato, Mary / Fajgenbaum, David C

Orphanet journal of rare diseases

2023 Volume 18, Issue 1, Page(s) 75

Abstract: Background: There are approximately 10,000 rare diseases that affect around 30,000,000 individuals in the U.S.A., most of which do not have an FDA-approved treatment. This fact highlights the failure of traditional research approaches to overcome the ... ...

Abstract	Background: There are approximately 10,000 rare diseases that affect around 30,000,000 individuals in the U.S.A., most of which do not have an FDA-approved treatment. This fact highlights the failure of traditional research approaches to overcome the unique challenges of developing rare disease treatments. The Castleman Disease Collaborative Network was founded in 2012 to advance research and treatments for Castleman disease, a rare and deadly disease that involves the immune system attacking the body's vital organs for an unknown cause. It has spearheaded a novel strategy for advancing biomedical research, the Collaborative Network Approach. This approach consists of eight steps, one of which is to identify and prioritize high-impact research questions through crowdsourcing ideas from the entire community of stakeholders: patients, loved ones, physicians, and researchers. Rather than hoping that the right researcher will apply for the right research project at the right time, crowdsourcing high-priority research projects into a research strategy ensures that the most high-impact, patient-centered studies are prioritized. The Castleman Disease Collaborative Network launched an initiative in 2021 to systematically generate this list of community-directed studies to focus Castleman disease research efforts. Results: The Castleman Disease Collaborative Network was able to successfully create a patient-centered research agenda through engaging the entire community of stakeholders. The community contributed important questions about Castleman disease, which were prioritized and reviewed by our Scientific Advisory Board, and the result was a finalized list of studies that address these prioritized questions. We were also able to generate a best practices list which can serve as a model that can be utilized for other rare diseases. Conclusion: Creating a patient-centered research agenda through crowdsourcing research ideas from the community is one of the most important ways that the Castleman Disease Collaborative Network operationalizes its commitment to keeping patients at the center of research and we hope that by sharing these insights we can assist other rare disease organizations to pursue a patient-centric approach.
MeSH term(s)	Humans ; Castleman Disease ; Rare Diseases ; Crowdsourcing ; Biomedical Research ; Research Design
Language	English
Publishing date	2023-04-11
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2225857-7
ISSN	1750-1172 ; 1750-1172
ISSN (online)	1750-1172
ISSN	1750-1172
DOI	10.1186/s13023-023-02678-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia.

Fajgenbaum, David C / Phillips, Alexis D

Clinical chemistry

2020 Volume 66, Issue 11, Page(s) 1378–1379

MeSH term(s)	Humans ; Hypergammaglobulinemia/complications ; Hypergammaglobulinemia/diagnosis ; Plasma Cells
Language	English
Publishing date	2020-11-03
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	80102-1
ISSN	1530-8561 ; 0009-9147
ISSN (online)	1530-8561
ISSN	0009-9147
DOI	10.1093/clinchem/hvaa156
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cytokine Storm.

Fajgenbaum, David C / June, Carl H

The New England journal of medicine

2020 Volume 383, Issue 23, Page(s) 2255–2273

MeSH term(s)	Autoimmune Diseases/complications ; Bacterial Infections/complications ; Blood Proteins/physiology ; COVID-19/complications ; Chemokines/physiology ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/physiopathology ; Cytokine Release Syndrome/therapy ; Cytokines/immunology ; Cytokines/physiology ; Humans ; Interleukins/physiology ; Virus Diseases/complications
Chemical Substances	Blood Proteins ; Chemokines ; Cytokines ; Interleukins
Language	English
Publishing date	2020-12-02
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMra2026131
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Teaching Old Drugs New Tricks: Statins for COVID-19?

Fajgenbaum, David C / Rader, Daniel J

Cell metabolism

2020 Volume 32, Issue 2, Page(s) 145–147

Abstract: The COVID-19 pandemic has driven unprecedented efforts to identify existing treatments that can be quickly and effectively repurposed to reduce morbidity and mortality. In this issue of Cell Metabolism, Zhang et al. (2020) report an association between ... ...

Abstract	The COVID-19 pandemic has driven unprecedented efforts to identify existing treatments that can be quickly and effectively repurposed to reduce morbidity and mortality. In this issue of Cell Metabolism, Zhang et al. (2020) report an association between statin use and improved outcomes in a large observational study of hospitalized COVID-19 patients. Given the widespread availability, low cost, and safety of statins, this promising result should be further investigated in randomized controlled trials.
MeSH term(s)	Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/drug therapy ; Cytokine Release Syndrome/drug therapy ; Drug Repositioning/methods ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Observational Studies as Topic ; Pandemics ; Pneumonia, Viral/drug therapy ; SARS-CoV-2
Chemical Substances	Hydroxymethylglutaryl-CoA Reductase Inhibitors
Keywords	covid19
Language	English
Publishing date	2020-07-24
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2176834-1
ISSN	1932-7420 ; 1550-4131
ISSN (online)	1932-7420
ISSN	1550-4131
DOI	10.1016/j.cmet.2020.07.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6169: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Overview of Castleman disease.

Dispenzieri, Angela / Fajgenbaum, David C

Blood

2020 Volume 135, Issue 16, Page(s) 1353–1364

Abstract: Castleman disease (CD) describes a group of at least 4 disorders that share a spectrum of characteristic histopathological features but have a wide range of etiologies, presentations, treatments, and outcomes. CD includes unicentric CD (UCD) and ... ...

Abstract	Castleman disease (CD) describes a group of at least 4 disorders that share a spectrum of characteristic histopathological features but have a wide range of etiologies, presentations, treatments, and outcomes. CD includes unicentric CD (UCD) and multicentric CD (MCD), the latter of which is divided into idiopathic MCD (iMCD), human herpes virus-8 (HHV8)-associated MCD (HHV8-MCD), and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD (POEMS-MCD). iMCD can be further subclassified into iMCD-thrombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS). Advances in diagnosis, classification, pathogenesis, and therapy are substantial since the original description of UCD by Benjamin Castleman in 1954. The advent of effective retroviral therapy and use of rituximab in HHV8-MCD have improved outcomes in HHV8-MCD. Anti-interleukin-6-directed therapies are highly effective in many iMCD patients, but additional therapies are required for refractory cases. Much of the recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and further progress will be made by continued engagement of physicians, scientists, and patients. Progress can also be facilitated by encouraging patients to self-enroll in the CDCN's ACCELERATE natural history registry (#NCT02817997; www.CDCN.org/ACCELERATE).
MeSH term(s)	Animals ; Castleman Disease/diagnosis ; Castleman Disease/pathology ; Castleman Disease/therapy ; Castleman Disease/virology ; Herpesviridae Infections/complications ; Herpesviridae Infections/diagnosis ; Herpesviridae Infections/therapy ; Herpesviridae Infections/virology ; Herpesvirus 8, Human/drug effects ; Herpesvirus 8, Human/isolation & purification ; Humans ; Immunologic Factors/therapeutic use ; Interleukin-6/antagonists & inhibitors ; Rituximab/therapeutic use
Chemical Substances	Immunologic Factors ; Interleukin-6 ; Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2020-02-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2019000931
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito